

In the Claims

1.-13. (Cancelled)

14. (Currently Amended) A method of amplifying activity of therapeutic vaccines, said method comprising administering an effective amount of a composition comprising a compound that depletes or inhibits B lymphocytes to a patient sufficient to amplify an immune reaction of T cytotoxic to a patient to augment the specific T-cell response to the therapeutic vaccine, wherein said composition comprises a monoclonal antibody directed against transmembrane antigen CD20 of pre-B or mature B lymphocytes, and wherein said therapeutic vaccine comprises an inactivated human immunodeficiency virus.

15. (Previously Presented) The method according to claim 14, wherein the B lymphocytes are naïve B lymphocytes.

16. (Currently Amended) The method according to claim 14, wherein the ~~immune reaction of the T cytotoxic lymphocytes~~ T-cell response is excited by a vaccination.

17. (Currently Amended) The method according to claim 16, wherein the vaccination is a vaccination against a ~~tumor and/or against a chronic viral, parasitic or intracellular germ~~ infection.

18. (Previously Presented) The method according to claim 16, wherein the vaccination is a therapeutic vaccination.

19. (Currently Amended) The method according to claim 14, wherein the ~~compound that depletes or inactivates the B lymphocytes~~ is a monoclonal ~~or polyclonal~~ antibody ~~[[or]]~~ is a Fab fragment of an antibody.

20.-21. (Cancelled)

22. (Currently Amended) The method according to claim 19, wherein the antibody is a murine/human chimeric antibody ~~obtained by genetic engineering.~~

23. (Currently Amended) The method according to claim 14, wherein the composition is administered prior to and/or concomitant with and/or subsequent to a vaccination against a ~~tumor~~ and/or against a chronic viral, ~~parasitic or intracellular germ~~ infection.

24. (Previously Presented) The method according to claim 23, wherein the vaccination is a therapeutic vaccination.

25.-26. (Cancelled)